Jefferies upgraded ICU Medical (ICUI) to Buy from Hold with an unchanged price target of $200. The firm continues to like ICU’s core infusion pump marker, which it says is supported by a “healthy” utilization environment with share gain and margin expansion opportunities. The pullback in the shares appears to bake in tariff risk, and the current valuation based “appears compelling relative to the company’s growth profile at twice peers,” the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICUI: